NCT01373528

Brief Summary

Chronic rhinosinusitis (CRS) is a complex inflammatory disease that is treated primarily with sinus surgery and the long-term use of topical steroid therapy. Budesonide irrigation is a common method of topical steroid treatment for these patients. However, the effects of budesonide irrigation on the hypothalamic-pituitary-adrenal (HPA) axis in patients with CRS following sinus surgery, is as of yet not defined. The objective of this study is to determine if topical sinonasal budesonide steroid irrigation leads to acute recoverable and/or long-term suppression of the HPA axis. Participants in this prospective cohort study will have CRS and have recently undergone endoscopic sinus surgery. They will also have had planned use of budesonide irrigations as their postoperative medical treatment. The acute effects of this treatment on the HPA axis will be evaluated using serial serum cortisol measurements both the day before and the day of the first budesonide irrigation. The long-term effect of sinonasal budesonide irrigation will be evaluated using both a pre- and post-treatment adrenocorticotropic hormone (ACTH) stimulation test as well as repeated urine free cortisol levels over the length of the study. The results will determine the need for additional steroids when patients stop treatment or with a physiologic stressful event.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Dec 2010

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2010

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

June 12, 2011

Completed
3 days until next milestone

First Posted

Study publicly available on registry

June 15, 2011

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2012

Completed
Last Updated

May 18, 2012

Status Verified

May 1, 2012

Enrollment Period

1.4 years

First QC Date

June 12, 2011

Last Update Submit

May 16, 2012

Conditions

Keywords

Sinonasal BudesonideEndoscopic sinus surgeryHypothalamic-Pituitary-Adrenal Axis Function

Outcome Measures

Primary Outcomes (3)

  • Serum cortisol levels before and after treatment

    12 months

  • ACTH stimulation test cortisol level

    12 months

  • Urinary Free Cortisol Levels

    Every 3 months

Study Arms (1)

Budesonide

EXPERIMENTAL
Drug: Budesonide irrigation

Interventions

A budesonide (1 mg) in saline (240 mL) irrigation solution is applied to the sinonasal cavities twice daily. 120 mL of the solution is applied via irrigation in the AM, and 120 mL again in the PM.

Budesonide

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Consenting adult patients (age ≥18) who are diagnosed with CRS
  • Patient already determined to need surgical treatment having failed medical management
  • Patients planned to be treated with budesonide irrigations as postoperative maintenance therapy

You may not qualify if:

  • Patients with pre-operative symptoms and signs of HPA dysfunction
  • Patients with signs and symptoms of untreated endocrine disorders such as hypothyroidism, hypopituitarism, hypogonadism. Screening for thyroid disease will be done with a TSH, T3 and free T4 for each participant.
  • Patients with known history of liver disease or abnormal AST/ALT lab tests
  • Any history of oral glucocorticoid use in the past 4 months
  • Patients with a known history of glaucoma
  • Patients with known tuberculosis (TB)- active or latent
  • Patients taking drugs that affect cortisol synthesis (mifepristomine, itraconazole, ketoconazole, erythromycin, clarithromycin, cimetidine) or protein binding drugs (estrogens and androgens)
  • A known sensitivity to topical budesonide
  • Pregnant and/or breast feeding woman
  • Presence of multiple co-morbidities such as poorly controlled diabetes, chronic renal failure, hepatic failure
  • Inability to provide informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ottawa Hospital Riverside Campus

Ottawa, Ontario, K1H 4E9, Canada

Location

Study Officials

  • Kilty Shaun, MD

    OHRI

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 12, 2011

First Posted

June 15, 2011

Study Start

December 1, 2010

Primary Completion

May 1, 2012

Study Completion

May 1, 2012

Last Updated

May 18, 2012

Record last verified: 2012-05

Locations